Companies: 10,795·Total market cap: $144.5T
Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc.

ERNANASDAQHealthcare● Active
$7.62
+$0.23(+3.11%)
Market Cap$2393625
P/E Ratio—
52W High$71.5
52W Low$3.18
Overview

Ernexa Therapeutics Inc. (ERNA) · Cash Flow

Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.

FMP · ERNA · as of 2026-06-10

Financial statements

Operating CF · CapEx · Free Cash Flow
Breakdown2025-122024-122023-122022-122021-12
Operating Activities
Net Income($0.01B)($0.04B)($0.02B)($0.02B)($0.12B)
Depreciation & Amort.$0.00B$0.00B$0.00B$0.00B$0.00B
Stock-Based Comp.$0.00B$0.00B$0.00B$0.00B$0.01B
Change in Working Capital($0.00B)($0.00B)($0.00B)$0.00B($0.00B)
Net Cash from Operations($0.01B)($0.02B)($0.02B)($0.02B)($0.02B)
Investing Activities
Capital Expenditure($0.00B)($0.00B)($0.00B)($0.00B)($0.00B)
Purchases of Investments$0.00B$0.00B$0.00B$0.00B$0.00B
Sales of Investments$0.00B$0.00B$0.00B$0.00B$0.00B
Net Cash from Investing($0.00B)($0.00B)($0.00B)($0.00B)($0.02B)
Financing Activities
Common Stock Repurchased$0.00B$0.00B$0.00B$0.00B$0.00B
Dividends Paid$0.00B$0.00B($0.00B)($0.00B)($0.00B)
Debt Issued / Repaid$0.00B$0.01B$0.02B($0.00B)($0.00B)
Net Cash from Financing$0.01B$0.01B$0.02B$0.02B$0.06B
Free Cash Flow
Free Cash Flow($0.01B)($0.02B)($0.02B)($0.02B)($0.02B)
FCF Margin %(computed)—————

Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B

SEC 10-K filings →SEC 10-Q filings →

Explore more Ernexa Therapeutics Inc. data

Revenue History
Quarterly & annual revenue trends
Earnings Reports
EPS beats, misses & upcoming dates
P/E Ratio
Historical price-to-earnings
Dividends
Dividend history & yield
Market Cap
Historical market cap & rank
Analyst Forecast
Consensus, price targets & estimates

About Ernexa Therapeutics Inc. (ERNA) Cash Flow Statement

Ernexa Therapeutics Inc. generated operating cash flow of ($0.01B) and free cash flow of ($0.01B) for 2025 — a FCF margin of —. Capital expenditure was ($0.00B).

Frequently asked questions

ERNA · 4 questions

Ernexa Therapeutics Inc. generated free cash flow of ($0.01B) for 2025, up 56.5% year-over-year.

ERNA free cash flowFCF margincash flow yield

· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10